title: [Over two years survival of intra-arterial infusion chemotherapy in gastric cancer with liver metastases].
abstract: Between 1977 and April in 1989, long-term survivors (over two years) by intra-arterial infusion chemotherapy in gastric cancer patients with liver metastases were examined. The materials were 5 patients (4 synchronous, 1 metachronous metastases) among 21 P0H (+) gastric cancers. The extent of liver metastases shows 1 H1 and 4 H2. Reduction surgery was performed in 4 H2 patients (2 S2 + 3, 1 S4, 1 S6) and postoperative intra-arterial infusion chemotherapy via the catheter in the common hepatic artery was done to control the residual liver metastases. Continuous intra-arterial infusion chemotherapy with the regimen of FML (5-FU, MMC, Lentinan) revealed 100% response rate (3 CR, 1 PR). In a patient with metachronous metastases, PR was obtained with MA (MMC, ADM) + one-shot intra-arterial infusion of LAK cells. Among 5 patients, one with synchronous metastases has survived 35 months, followed by a patient who died after 32 months and two patients who died after 27 months. A patient with metachronous metastases has survived for 24 months.
authors.affiliation: Second Dept. of Surgery, Chiba University.
authors.forename: K
authors.initials: K
authors.lastname: Okuyama
authors.forename: S
authors.initials: S
authors.lastname: Onoda
authors.forename: N
authors.initials: N
authors.lastname: Tohnosu
authors.forename: Y
authors.initials: Y
authors.lastname: Koide
authors.forename: T
authors.initials: T
authors.lastname: Awano
authors.forename: M
authors.initials: M
authors.lastname: Ozaki
authors.forename: T
authors.initials: T
authors.lastname: Ochiai
authors.forename: Y
authors.initials: Y
authors.lastname: Gunji
authors.forename: H
authors.initials: H
authors.lastname: Matsubara
authors.forename: H
authors.initials: H
authors.lastname: Kinoshita
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000627:therapeutic use; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000008:administration & dosage; D005472:Fluorouracil / Q000008:administration & dosage; D006499:Hepatic Artery; D006801:Humans; D007261:Infusions, Intra-Arterial; D007912:Lentinan / Q000008:administration & dosage; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary; D008297:Male; D008875:Middle Aged; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage; D012074:Remission Induction; D013274:Stomach Neoplasms / Q000473:pathology*
chemical_list: D008937:Mitomycins; D007912:Lentinan; D016685:Mitomycin; D004317:Doxorubicin; D005472:Fluorouracil